Farklı Hematopoetik Kök Hücre Kaynaklarının Koloni Colony Forming Unit-Assay Oluşturma Kapasitelerinin Karşılaştırılması

Abstract

Giriş ve Amaç: Günümüzde Hematopoetik Kök Hücre Nakli (HKHN) özellikle hematolojik malignitelerin tedavisinde başarıyla uygulanmaktadır. Hematopoetik kök hücre (HKH) kaynağı olarak allojenik nakillerde genellikle direkt kemik iliğinden, otolog nakillerde ise genellikle kemik iliğinden mobilize edilip periferik kandan elde edilen hematopoetik kök hücreler kullanılmaktadır. Bu çalışmada farklı kaynaklardan elde edilen hematopoetik kök hücrelerin koloni oluşturma kapasitelerinin karşılaştırılması amaçlandı.Gereç ve Yöntemler: Hematopoetik kök hücre örnekleri 7 olguda direk kemik iliğinden, 7 olguda da periferik kandan elde edildi. Elde edilen hematopoetik kök hücrelerle invitro hücre kültür ortamlarına alındı. Periferik kan ve kemik iliği kaynaklı HKH örnekleri uygun Semi-Solid Agar besiyerinde (Methocult, H 4434 Classic, Stem Cell Technologies, Canada) kültüre edilerek 14-18 gün sonra koloni sayıları belirlenerek Colony Forming Unit Assay (CFU-Assay) hesaplandı.Bulgular: Otolog 7 vericiden alınan periferik kan HKH örneklerinin koloni sayımlarının ortalamaları CFU-GM:28.44x104/kg, BFU-E:40.7x104/kg, CFU-E:0.79x104/kg, CFU-GEMM :1.95x104/kg. Allojenik 7 vericiden alınan kemik iliği HKH örneklerinin Koloni sayımlarının ortalamaları CFU-GM:7.03x104/kg, BFU-E:10.46x104/kg, CFU-E:0.16x104/kg, CFU-GEMM :0.51x104/kg.Sonuç: CFU-Assay ile değerlendirilen periferik kan kaynaklı HKH kolonilerinin sayısı kemik iliği kaynaklı HKH kolonilere göre daha yüksek bulundu. Hematopoetik kök hücre nakillerinde özellikle erişkinlerde periferik kan kaynaklı hematopoetik kök hücrelerin kullanımı giderek yaygınlaşmaktadır. Pediatrik grupta da klinik verilerle invitro hücre kültür bulgularının desteklenmesi periferik kan kaynaklı HKH kullanımı için tercih sebebi olabilir.

Keywords

• Kök hücre, CFU-Assay, hematopoetik kök hücre nakli

COMPARISON OF COLONY FORMING UNIT-ASSAY RESULTS OF DIFFERENT HEMATOPOIETIC STEM CELL SOURCES

Abstract

Aim: Hematopoietic stem cell transplantation (HSCT) is practiced successfully especially for hematologic malignancies. The source of hematopoietic stem cells for HSCT is bone marrow in allogeneic transplantation or peripheral blood stem cells after mobilization in autologous transplantation. The aim of this study is to investigate CFU-ASSAY results of two different hematopoietic stem cell sources.Method: Hematopoietic stem cells collected from bone marrow in 7 patients and peripheral blood in 7 patients were included in the study. Hematopoietic stem cells were cultured in semi-solid agar culture medium (Methocult, H 4434 Classic, Stem Cell Technologies, Canada) and CFU-ASSAY was performed after 14-18 day of culture period for each group.Results: CFU-Assay results of peripheral blood stem cells for autologous donors were as follows; CFUGM:28.44x104/kg, BFU-E:40.7x104/kg, CFU-E:0.79x104/kg, CFU-GEMM :1.95x104/kg. CFU-Assay results of bone marrow stem cells for allogeneic donors were as follows; CFU-GM:7.03x104/kg, BFUE:10.46x104/kg, CFU-E:0.16x104/kg, CFU-GEMM:0.51x104/kg.Conclusion: CFU-Assay results revealed that colony forming capacity of peripheral blood stem cells are higher than that of bone marrow stem cells. Peripheral blood stem cells transplantation is becoming more prevalent especially in adults. In pediatric groups, to identify the correlation between invitro results and clinical observations may help to increase preferance of peripheral blood stem cell transplantation

Keywords

• Stem Cell, CFU-Assay, hematopoietic stem cell transplantation

References

1. Thomas ED, Lochte HL, Lu WC, Ferrebee JW. Intravenous infu- sion of bone marrow in patients receiving radiation and chemo- therapy. N Eng J Med 1957;257(11):491-6.
2. Thomas ED, Lochte HL Jr, Canon JH, Sahler OD, Ferrebee JW. Supralethal whole body irradiation and isologous marrow trans- plantation in man. J Clin Investigat 1959;38:1709-16.
3. Thomas ED, Collins JA, Herman EC, Ferrebee JW. Marrow transplants in lethally irradiated dogs given methotrexate. Blood 1962;19:217-28.
4. Thomas ED, Buckner CD, Storb R, Neiman PE, Fefer A, Clift RA, et al. Aplastic anaemia treated by marrow transplantation. Lancet 1972;1(7745)284-9.
5. Thomas ED, Storb R, Clift RA, Fefer A, Johnson FL, Neiman PE, et al. Bone marrow transplantation (second of two parts). N Eng J Med 1975;292(17):895-902.
6. Thomas ED, Flournoy N, Buckner CD, Clift RA, Fefer A, Neiman PE, et al. Cure of leukemia by marrow transplantation. Leukemia Research 1977;1(1):67-70.
7. Good RA, Meuwissen HJ, Hong R, Gatti RA. Bone marrow trans- plantation: correction of immune deficit in lymphopenic immu- nologic deficiency and correction of an immunologically induced pancytopenia. Trans Assoc Am Physicians 1969;82:278-85.
8. Good RA, Gatti RA, Hong R, Meuwissen HJ. Graft treatment of immunological deficiency. Lancet 1969;1(7606):1162.

9. Boyiadzis M, Pavletic S. Haematopoetic stem cell transplantation: indications, clinical developments and future directions. Expert Opin Pharmacother 2004;5(1):97-108.
10. Barrett D, Fish JD, Grup SA. Autologous and allogeneic cellular therapies for high-risk pediatric solid tumors. Pediatr Clin North Am 2010;57(1):47-66.
11. Milanetti F, Agabeynun M, Voltarelli JC, Burt RK. Autologous hematopoietic stem cell transplantation for childhood autoimmune disease. Pediatr Clin North Am 2010;57(1):239-71.
12. Berenson RJ, Bensinger WI, Hill RS, Andrews RG, Garcia-Lopez J, Kalamasz DF, et al. Engraftment after infusion of CD34+ mar- row cells in patients with breast cancer or neuroblastoma. Blood 1991;77(8):1717-22.
13. Goodman JW, Hodgson GS. Evidence fors tem cells in the periph- eral blood of mice. Blood 1962;19:702-14.
14. Cavins JA, Kasakura S, Thomas ED, Ferrebee JW. Recovery of lethally irradiated dogs following infosion of autologous mar- row stored at low temperature in dimethyl-sulphoxide. Blood 1962;20:730-734.
15. Storb R, Graham TC, Epstein RB, Sale GE, Thomas ED. Dem- onstration of hematopoietic stem cells in the peripheral blood of baboons by cross circulation. Blood 1977;50(3):537-42.
16. Kessinger A, Armitage JO, Landmark JD, Smith DM, Weisenburg- er DD. Autologous peripheral hematopoietic stem cell transplan- tation restores hematopoietic function following marrow ablative therapy. Blood 1988;71(3):723-7.
17. Gianni AM, Siena S, Bregni M, Tarella C, Stern AC, Pileri A, et al. Granulocyte-macrophage colony-stimulating factor to harvest circulating haemopoietic stem cells for autotransplantation. Lancet 1989;2(8663):580-5.
18. Storek J, Gooley T, Siadak M, Bensinger WI, Maloney DG, Chauncey TR, et al. Allogeneic peripheral blood stem cell trans- plantation may be associated with a high risk of chronic graft-ver- sus-host disease. Blood 1997;90(12):4705-9.
19. Liton JM. Peripheral blood as a stem cell source for hematopoietic cell transplantation in children: is the effort in vein? Pediatr Trns- plantation 2003;7 supple 3:65-70.
20. Coulombel L. Identification of hematopoietic stem/progenitor cells: strength and drawbacks of functional assays. Oncogene 2004:23(43):7210-22.